Overview
- The FDA issued Modified Risk Tobacco Product orders on Tuesday allowing 20 Zyn nicotine‑pouch variants to be marketed with the claim that switching from cigarettes lowers the risk of six smoking‑related diseases.
- The authorization covers 10 flavors sold at two nicotine strengths, 3 mg and 6 mg, and applies only to the specific listed products rather than to all nicotine pouches.
- Agency reviewers concluded Swedish Match provided scientific and consumer‑understanding evidence showing the claim is accurate and that marketing these products would benefit the population as a whole.
- The orders carry conditions including compulsory postmarket surveillance and user‑perception studies, a five‑year expiration, and explicit FDA authority to rescind the claims if youth uptake or other population harms increase.
- Public‑health groups voiced strong alarm over youth use and the products not being approved as cessation aids, while Philip Morris/Swedish Match and some market analysts called the decision a major regulatory milestone for the nicotine‑pouch category.